A pivotal Phase 3 trial of CK-101 in treatment-naive EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Mar 2021 Status changed from planning to recruiting (as of Nov 2020), according to a Checkpoint Therapeutics media release.
09 Mar 2021 According to a Checkpoint Therapeutics media release, the company plans to meet with the FDA to discuss the ongoing Phase 3 study design and its potential use and upon a successful study, to support a new drug application submission in the United States.
08 Aug 2019 According to a Checkpoint Therapeutics media release, the company plans to begin this trial in 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com